ClinicalTrials.gg
CompletedNCT04666688Updated Nov 16, 2026Results posted

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

A Phase 1/2 interventional study of LYT-200 and Tislelizumab in Metastatic Cancer, Solid Tumor and Head and Neck Cancer, sponsored by PureTech. Completed at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by PureTech · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 16, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
44
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,057 studies in Neoplasm Metastasis with a site in United States — 344 open to participants now, 544 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Enrollment
908th of 1,866
44 · median 43
Started
2020
with 88 others
Phase 1/2
268 of 2,057
62 open now
Registered
1,475th of 2,057
by date

Among the 2,057 studies in Neoplasm Metastasis with a site in United States, this one is the 908th largest by enrollment of the 1,866 interventional ones that give a count, is one of 89 that started in 2020, is one of 268 in phase 1/2, and was the 1,475th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

344 of the 2,057 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

339 more — sign in →

All 344 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,057 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or tislelizumab in Patients with Metastatic Solid Tumors

Read the detailed description

This is an open-label, non-randomized, multicenter Phase 1/2 study with a dose escalation phase (Part 1) and a cohort expansion phase (Part 2) in patients with relapsed/refractory metastatic solid tumors.

Part 1: Dose Escalation Phase_Single Agent A dose-finding study will be conducted using a continuous reassessment method (CRM) to establish dose-limiting toxicities (DLTs) and the recommended Phase 2 dose (RP2D).

Part 1: Dose Escalation Phase_Combination A dose-finding combination study with chemotherapy or tislelizumab will be conducted using a 4+2 study design to establish dose-limiting toxicities (DLTs) and the recommended Phase 2 dose (RP2D).

Part 2: Was not initiated

03

Conditions studied

  • Metastatic Cancer
  • Solid Tumor
  • Head and Neck Cancer

Keywords

  • Metastatic cancer
  • Solid tumors
  • Combination therapy
  • Head and Neck Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part 1

  1. Written (mentally competent patient, able to understand and willing to sign the informed consent form)
  2. Age ≥ 18 years, male or non-pregnant female
  3. Able to comply with the study protocol, as per Investigator's judgment
  4. confirmed, unresectable locally advanced or cancer. There are no limits to received for the treatment of the cancer condition for which the patient is being enrolled into this study.

    1. For the Part 1 combination urothelial carcinoma Cohorts 13 and 14: histologically or cytologically confirmed diagnosis of unresectable, locally advanced or metastatic urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra (i.e., transitional cell carcinoma).
    2. For the Part 1 combination H/N cancer Cohorts 11 and 12: histologically confirmed, locally advanced or metastatic squamous cell carcinoma of head and neck (SCCHN; oral cavity, oropharynx, hypopharynx, or larynx).
  5. For urothelial and H/N combination cancer cohorts, prior exposure to immunotherapy is allowed, with standard of care treatment options and/or within a clinical trial context. If the patient received an and/or an anti-PD-L1 containing regimen at any point, they must have demonstrated at least stable disease, as per 1.1 or criteria to one of these treatment regimens, if these measurements are available. If RECIST or iRECIST measurements are not available, then clinical PFS of at least 4 months is required to have been achieved on any of the prior anti-PD-1 and/or anti-PD-L1 containing regimens.
  6. There is no PD-L1 expression requirement for the Part 1 combination urothelial and H/N cohorts; however, fresh or archival tissue is required for assessment of PD-L1 by IHC, or a historical PD-L1 expression by IHC must be available. If PD-L1 expression data are already available, this does not override the protocol preference for obtaining a fresh biopsy whenever feasible.
  7. For Part 1 combination cohort H/N cancer patients of oropharynx origin: human papilloma virus (HPV) status needs to be established in the screening period or at any point while patient is on study drug, unless it is historically known. p16+ as a surrogate for HPV+, HPV RNA ISH or DNA PCR are all acceptable. The study accepts both HPV+ and HPV- patients.
  8. > 3 months according to Investigator's judgment
  9. performance status 0-1
  10. Patient able and willing to undergo pre- and on/post treatment biopsies. According to the Investigator's judgment, the planned biopsies should not expose the patient to substantially increased risk of complications. Every effort will be made that the same lesion is biopsied on repeat biopsies. If the patient is eligible according to all other criteria but declines to consent to a biopsy or there are other medical reasons precluding biopsy, this will be discussed with the Sponsor.
  11. , according to RECIST v1.1. Note that lesions intended to be biopsied should not be target lesions.
  12. Adequate hematologic and end organ function, defined by the following laboratory results obtained prior to first dose of study drug treatment, provided no anticancer treatment was administered within the last 7 days:

    1. ≥ 1 x 109/L
    2. count ≥ 100 x 109/L; for hepatocellular carcinoma (HCC) in Part 1 ≥ 50 x 109/L
    3. ≥ 9.0 g/dL without transfusion in the previous week
    4. creatinine ≤ 1.5 x the (ULN); or > 50 mg/mmol
    5. AST (SGOT) ≤ 3 x ULN (≤ 5 x ULN when HCC or hepatic metastases are present)
    6. alanine aminotransferase (ALT [SGPT]) ≤ 3 x ULN (≤ 5 x ULN when HCC or hepatic metastases present)
    7. ≤ 1.5 x ULN (patients with known Gilbert's disease may have a bilirubin ≤ 3.0 x ULN)
    8. albumin ≥ 3.0 g/dL
    9. (INR) and partial thromboplastin time (PTT) ≤ 1.5 x ULN, unless patient receiving anticoagulant therapy
  13. No evidence of active serious infection or infections requiring parenteral antibiotics.
  14. Women of must have a negative pregnancy test within 72 h prior to start of treatment. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or to use methods that result in a failure rate of \< 1% per year during the treatment period and for at least 180 days after the last study treatment.

    A woman is of childbearing potential if she is post-menarche, has not reached a state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).

    Examples of contraceptive methods with a failure rate of \< 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptom-thermal, or post ovulation methods) and withdrawal are not acceptable methods of contraception. Fertile men must practice effective contraceptive methods during the study, unless documentation of infertility exists.

  15. Four (4) weeks or 5 half-lives (whichever is shorter) since the last dose of anticancer therapy before the first LYT-200 administration
  16. Bisphosphonate treatment (e.g., zoledronic acid) or denosumab are allowed if previously used prior to commencement of clinical trial.
  17. Patients:

    1. who have already received at least one prior line of systemic therapy for metastatic or locally advanced disease, and/or
    2. who have a tumor type for which there are no available standard of care options
  18. Patients who have not previously received a gemcitabine-containing regimen

Exclusion criteria

Exclusion Criteria

  1. Patient unwilling or unable to follow protocol requirements
  2. Patient diagnosed with cancer of an unknown primary
  3. Current illicit drug addiction (medical and recreational marijuana/cannabidiol [CBD]/ tetrahydrocannabinol [THC] would not be considered "illicit")
  4. , active uncontrolled bleeding, and any patients with a bleeding diathesis (e.g., active peptic ulcer disease). Prophylactic or therapeutic use of anticoagulants is allowed.
  5. Pregnant and/or lactating females
  6. Receiving any other agents or participating in any other clinical trial involving another investigational agent for treatment of solid tumors within 3 weeks or 5 half-lives of the administered drug (whichever is shorter) prior to the first dose of study drug, or major surgery or planned surgery within 4 weeks of the first dose of study drug (this includes dental surgery).
  7. Radiation therapy within 4 weeks of the first dose of study drug, except for palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tumor mass, and which does not jeopardize required for response assessment ( v1.1).
  8. Patients with fungating tumor masses
  9. History or current evidence of any condition, therapy, any active infections, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator
  10. Grade 4 immune-mediated toxicities with a prior . Grade 2 or Grade 3 pneumonitis or any other Grade 3 checkpoint inhibitor-related toxicity that led to immunotherapy treatment discontinuation. Low-grade (\< Grade 3) toxicities, such as neuropathy from prior treatments, manageable electrolyte abnormalities and lymphopenia, alopecia and vitiligo are allowed.
  11. History of other prior or other concomitant that requires other active treatment.
  12. Active parenchymal , patients with carcinomatous meningitis or . Patients with brain metastases are eligible provided they have shown clinically and radiographically stable disease for at least 4 weeks after definitive therapy and have not used (> 10 mg/day of prednisone or equivalent) for at least 4 weeks prior to the first dose of study drug
  13. Evidence of severe or uncontrolled systemic diseases, congestive heart failure > (NYHA) class 2, myocardial infarction (MI) within 6 months, or laboratory finding that in the view of the Investigator makes it undesirable for the patient to participate in the trial
  14. Any medical condition that the Investigator considers significant to compromise the safety of the patient or that impairs the interpretation of LYT-200 toxicity assessment
  15. Serious non-healing wound, active ulcer, or untreated bone fracture unless for e.g., a rib fracture for (which does not elicit treatment)
  16. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures. For the purposes of this study, "recurrent" is defined as ³ 3 drains in the last 30 days
  17. History of severe allergic, anaphylactic, or other reactions to chimeric or humanized antibodies or fusion proteins
  18. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months of Cycle 1, Day 1
  19. History of pulmonary embolism, stroke or within 3 months prior to Cycle 1, Day 1
  20. Active disorder (except type I/II diabetes, hypothyroidism requiring only hormone replacement, vitiligo, psoriasis, or alopecia areata).
  21. Requires systemic treatment, including, but not limited to cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor (anti-TNF) agents. Patients who have received or are receiving acute, low dose systemic immunosuppressant medications (e.g., ≤ 10 mg/day of prednisone or equivalent) may be enrolled. Replacement therapy (e.g., thyroxine, insulin, physiologic corticosteroid replacement therapy [e.g., ≤ 10 mg/day of prednisone equivalent] for adrenal or pituitary insufficiency) is not considered a form of systemic treatment. The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone), topical steroids, intranasal steroids, intra-articular, and ophthalmic steroids is allowed.
  22. Severe tumor-related pain (Grade 3, v.5.0) unresponsive to broad analgesic interventions (oral and/or patches)
  23. Hypercalcemia (defined as ³ Grade 3, per CTCAE v 5.0) despite use of bisphosphonates
  24. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk of treatment complications
  25. Received organ transplant(s)
  26. Patients undergoing dialysis
  27. For Part 1, hormonal androgen deprivation therapy is allowed to continue for patients with metastatic castration-resistant prostate cancer
  28. Any ablative therapy (Radio Frequency Ablation or Percutaneous Ethanol Injection) for HCC \< 6 weeks prior trial entry
  29. Hepatic encephalopathy or severe liver adenoma
  30. score ≥ 7
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Part 1 Cohort 1 0.2 mg/kg LYT-200 every 2 weeks

    Part 1 Cohort 1 Single Agent Cohort LYT-200 0.2 mg/kg every 2 weeks in metastatic solid tumors

    Drug: LYT-200

  • Experimental
    Part 1 Cohort 2 0.63 mg/kg LYT-200 every 2 weeks

    Part 1 Cohort 2 Single Agent Cohort LYT-200 0.63 mg/kg every 2 weeks in metastatic solid tumors

    Drug: LYT-200

  • Experimental
    Part 1 Cohort 3 2 mg/kg LYT-200 every 2 weeks

    Part 1 Cohort 3 Single Agent Cohort LYT-200 2 mg/kg every 2 weeks in metastatic solid tumors

    Drug: LYT-200

  • Experimental
    Part 1 Cohort 4 6.3 mg/kg LYT-200 every 2 weeks

    Part 1 Cohort 4 Single Agent Cohort LYT-200 6.3 mg/kg every 2 weeks in metastatic solid tumors

    Drug: LYT-200

  • Experimental
    Part 1 Cohort 5 10 mg/kg LYT-200 every 2 weeks

    Part 1 Cohort 5 Single Agent Cohort LYT-200 10 mg/kg every 2 weeks in metastatic solid tumors

    Drug: LYT-200

  • Experimental
    Part 1 Cohort 6 16 mg/kg LYT-200 every 2 weeks

    Part 1 Cohort 6 Single Agent Cohort LYT-200 10 mg/kg every 2 weeks in metastatic solid tumors

    Drug: LYT-200

  • Experimental
    Part 1 Cohort 7 10 mg/kg LYT-200 weekly

    Part 1 Cohort 7 Single Agent Cohort LYT-200 0.2 mg/kg weekly in metastatic solid tumors

    Drug: LYT-200

  • Experimental
    Part 1 Cohort 11 6.3 mg/kg LYT-200 + tislelizumab weekly

    Part 1 Cohort 11 LYT-200 6.3 mg/kg weekly in combination with Tislelizumab in head and neck cancers

    Drug: LYT-200 · Drug: Tislelizumab

  • Experimental
    Part 1 Cohort 12 16 mg/kg LYT-200 + tislelizumab weekly

    Part 1 Cohort 12 LYT-200 16 mg/kg weekly in combination with Tislelizumab in head and neck cancers

    Drug: LYT-200 · Drug: Tislelizumab

  • Experimental
    Part 1 Cohort 13 6.3 mg/kg LYT-200 + tislelizumab weekly

    Part 1 Cohort 13 LYT-200 6.3 mg/kg weekly in combination with Tislelizumab in Urothelial Carcinoma

    Drug: LYT-200 · Drug: Tislelizumab

Interventions

  • DrugLYT-200

    monoclonal antibody (mAb), targeting galectin-9 protein

  • anti-PD-1 monoclonal antibody

06

What researchers measure

Primary outcomes

  1. Part 1: Incidence of Treatment-Emergent Adverse Events [Safety]

    Evaluation of safety parameters including treatment emergent adverse events as detected by hematology, chemistry, coagulation safety labs, physical exams, vital signs, ECG, ECHO/MUGA, ECOG status.

    Time frame: approximately 1 year

  2. Part 1: Incidence of Dose Limiting Toxicities [Tolerability]

    Evaluation of tolerability parameters including dose limiting toxicities as detected by hematology, chemistry, coagulation safety labs, physical exams, vital signs, ECG, ECHO/MUGA, ECOG status

    Time frame: approximately 1 year

07

Results

Posted Nov 16, 2026

Participant flow

Participant flow — Overall Study
MilestoneCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Cohort 7Cohort 11Cohort 12Cohort 13
Started22322361275
Completed0101000000
Not completed21312361275

Outcome measures

PrimaryPart 1: Incidence of Treatment-Emergent Adverse Events [Safety]

Evaluation of safety parameters including treatment emergent adverse events as detected by hematology, chemistry, coagulation safety labs, physical exams, vital signs, ECG, ECHO/MUGA, ECOG status.

Time frame:
approximately 1 year
Reported as:
Count of participants · Participants
Part 1: Incidence of Treatment-Emergent Adverse Events [Safety]
ParticipantsCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Cohort 7Cohort 11Cohort 12Cohort 13
Part 1: Incidence of Treatment-Emergent Adverse Events [Safety]22312361265
PrimaryPart 1: Incidence of Dose Limiting Toxicities [Tolerability]

Evaluation of tolerability parameters including dose limiting toxicities as detected by hematology, chemistry, coagulation safety labs, physical exams, vital signs, ECG, ECHO/MUGA, ECOG status

Time frame:
approximately 1 year
Reported as:
Count of participants · Participants
Part 1: Incidence of Dose Limiting Toxicities [Tolerability]
ParticipantsCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Cohort 7Cohort 11Cohort 12Cohort 13
Part 1: Incidence of Dose Limiting Toxicities [Tolerability]0000000000

Adverse events

Collected over 4 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 10/2 (0%)1/2 (50%)2/2 (100%)
Cohort 20/2 (0%)0/2 (0%)2/2 (100%)
Cohort 30/3 (0%)2/3 (66.7%)3/3 (100%)
Cohort 40/2 (0%)0/2 (0%)1/2 (50%)
Cohort 50/2 (0%)1/2 (50%)2/2 (100%)
Cohort 61/3 (33.3%)2/3 (66.7%)3/3 (100%)
Cohort 70/6 (0%)1/6 (16.7%)6/6 (100%)
Cohort 112/12 (16.7%)7/12 (58.3%)9/12 (75%)
Cohort 120/7 (0%)2/7 (28.6%)5/7 (71.4%)
Cohort 130/5 (0%)4/5 (80%)4/5 (80%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Cohort 7Cohort 11Cohort 12Cohort 13
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/20/20/30/20/20/30/60/120/70/5
Groin PainMusculoskeletal and connective tissue disorders1/20/20/30/20/20/30/60/120/70/5
Pain in ExtremityMusculoskeletal and connective tissue disorders0/20/20/30/21/20/30/60/120/70/5
VIth nerve disorderNervous system disorders0/20/20/30/21/20/30/60/120/70/5
HaematomaVascular disorders1/20/20/30/20/20/30/60/120/70/5
Abdominal PainGastrointestinal disorders0/20/21/30/20/20/30/60/120/70/5
Intestinal PerforationGastrointestinal disorders0/20/20/30/20/21/30/60/120/70/5
Lower Gastrointestinal HaemorrhageGastrointestinal disorders0/20/21/30/20/20/30/60/120/70/5
Pleural effusionRespiratory, thoracic and mediastinal disorders0/20/20/30/20/21/31/61/120/70/5
SepsisInfections and infestations0/20/20/30/20/20/30/61/120/71/5
Most frequent other events
Showing 10 of 46
Most frequent other events
EventCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Cohort 7Cohort 11Cohort 12Cohort 13
Decreased appetiteMetabolism and nutrition disorders0/20/20/30/21/23/31/61/120/71/5
Peripheral oedemaGeneral disorders0/20/22/30/21/20/30/60/120/70/5
Abdominal painGastrointestinal disorders0/21/22/30/20/20/30/62/120/70/5
Abdominal distentionGastrointestinal disorders0/20/22/30/20/20/30/62/120/71/5
DiarrhoeaGastrointestinal disorders0/20/21/31/20/20/32/61/122/73/5
HypokalaemiaMetabolism and nutrition disorders0/20/21/31/20/21/31/60/120/70/5
Infusion related reactionInjury, poisoning and procedural complications0/21/20/30/20/20/31/60/120/70/5
Back painMusculoskeletal and connective tissue disorders1/20/20/30/21/20/32/63/122/72/5
FatigueGeneral disorders0/20/21/30/21/21/33/65/122/72/5
ConstipationGastrointestinal disorders1/20/20/30/21/20/31/62/122/70/5

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Cohort 7Cohort 11Cohort 12Cohort 13Total
<=18 years00000000000
Between 18 and 65 years102201463120
>=65 years121022264424
Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Cohort 7Cohort 11Cohort 12Cohort 13Total
Mean68.5 ± 23.3367.5 ± 2.1260.7 ± 17.9561.0 ± 1.4177.5 ± 0.7173.3 ± 14.5759.8 ± 9.8763.4 ± 8.1364.1 ± 10.4270.8 ± 7.0965.4 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Cohort 7Cohort 11Cohort 12Cohort 13Total
Female112101312012
Male1111223115532
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Cohort 7Cohort 11Cohort 12Cohort 13Total
Race — American Indian or Alaska Native00000000000
Race — Asian00000001001
Race — Native Hawaiian or Other Pacific Islander00000000000
Race — Black or African American00000000000
Race — White221211495431
Race — More than one race00000000000
Race — Unknown or Not Reported002012222112
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Cohort 7Cohort 11Cohort 12Cohort 13Total
Hispanic or Latino00001000102
Not Hispanic or Latino2222135115336
Unknown or Not Reported00100011126
Region of Enrollment
Region of Enrollment(participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Cohort 7Cohort 11Cohort 12Cohort 13Total
United States2232236127544
08

Study locations

13 sites
  • UCLA
    Los Angeles, California 90095, United States
  • University of Colorado Hospital
    Denver, Colorado 80045, United States
  • Sarah Cannon Research Institute at Health One
    Denver, Colorado 80218, United States
  • Sarah Cannon Research Institute, Florida Cancer Specialists
    Sarasota, Florida 34232, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • South Texas Accelerated Research Therapeutics
    Grand Rapids, Michigan 49546, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Columbia University
    New York, New York 10027, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • Sarah Cannon Research Institute, Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • University of Texas, M.D. Anderson Cancer Center
    Houston, Texas 77030, United States
  • South Texas Accelerated Research Therapeutics
    San Antonio, Texas 78229, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Dec 2024, 48 months.

Results were first posted in Nov 2026, 1 year 11 months after primary completion.

Of 129 industry-sponsored phase 1/2 interventional studies under Neoplasm Metastasis, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 89. This study's 48 months is below that.

Counting every sponsor, half of 215 studies reached it within 62 months; a quarter within 42 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2020
First posted
Dec 14, 2020
StartActual
Dec 11, 2020
Primary completionActual
Dec 12, 2024
CompletionActual
Dec 12, 2024
Results first posted
Nov 16, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 16, 2026
Sites
1 site added
Show site
  • Mayo Clinic · Rochester, United States
Nov 16, 2026
Start date
Dec 15, 2020→Dec 11, 2020
Nov 16, 2026
Interventions
Removed Drug: Gemcitabine/nab-paclitaxel. Arms added: Part 1 Cohort 1 0.2 mg/kg LYT-200 every 2 weeks·Part 1 Cohort 2 0.63 mg/kg LYT-200 every 2 weeks·Part 1 Cohort 3 2 mg/kg LYT-200 every 2 weeks·Part 1 Cohort 4 6.3 mg/kg LYT-200 every 2 weeks·Part 1 Cohort 5 10 mg/kg LYT-200 every 2 weeks·and 5 more
All 10

Part 1 Cohort 1 0.2 mg/kg LYT-200 every 2 weeks · Part 1 Cohort 2 0.63 mg/kg LYT-200 every 2 weeks · Part 1 Cohort 3 2 mg/kg LYT-200 every 2 weeks · Part 1 Cohort 4 6.3 mg/kg LYT-200 every 2 weeks · Part 1 Cohort 5 10 mg/kg LYT-200 every 2 weeks · Part 1 Cohort 6 16 mg/kg LYT-200 every 2 weeks · Part 1 Cohort 7 10 mg/kg LYT-200 weekly · Part 1 Cohort 11 6.3 mg/kg LYT-200 + tislelizumab weekly · Part 1 Cohort 12 16 mg/kg LYT-200 + tislelizumab weekly · Part 1 Cohort 13 6.3 mg/kg LYT-200 + tislelizumab weekly

; arms removed: Part 1 single agent dose escalation·Part 1 combination agents dose expansion·Part 2
Nov 16, 2026
Primary outcomes
1 removed
What changed in the outcomes
  • RemovedPart 2: PFS or ORR [Preliminary Efficacy]Time frame: approximately 1 year
Nov 16, 2026
Documents
Secondary outcomes
4 removed
What changed in the outcomes
  • RemovedPart 1: Pharmacokinetic (PK) profile of LYT-200: Maximum Plasma Concentration [Cmax]Time frame: approximately 1 year
  • RemovedPart 1: Pharmacokinetic (PK) profile of LYT-200: Time to Maximum Plasma Concentraton [Tmax]Time frame: approximately 1 year
  • RemovedPart 1: Pharmacokinetic (PK) profile of LYT-200: Area Under the Curve [AUC]Time frame: approximately 1 year
  • RemovedPart 1: Pharmacodynamics (PD) of LYT- 200Time frame: approximately 1 year
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Results posted
    1 site added
    Show site
    • Mayo Clinic · Rochester, United States
    Start date Dec 15, 2020→Dec 11, 2020
    Primary outcomes 1 removed
    What changed in the outcomes
    • RemovedPart 2: PFS or ORR [Preliminary Efficacy]Time frame: approximately 1 year
    Secondary outcomes 4 removed
    What changed in the outcomes
    • RemovedPart 1: Pharmacokinetic (PK) profile of LYT-200: Maximum Plasma Concentration [Cmax]Time frame: approximately 1 year
    • RemovedPart 1: Pharmacokinetic (PK) profile of LYT-200: Time to Maximum Plasma Concentraton [Tmax]Time frame: approximately 1 year
    • RemovedPart 1: Pharmacokinetic (PK) profile of LYT-200: Area Under the Curve [AUC]Time frame: approximately 1 year
    • RemovedPart 1: Pharmacodynamics (PD) of LYT- 200Time frame: approximately 1 year
    Interventions Removed Drug: Gemcitabine/nab-paclitaxel. Arms added: Part 1 Cohort 1 0.2 mg/kg LYT-200 every 2 weeks·Part 1 Cohort 2 0.63 mg/kg LYT-200 every 2 weeks·Part 1 Cohort 3 2 mg/kg LYT-200 every 2 weeks·Part 1 Cohort 4 6.3 mg/kg LYT-200 every 2 weeks·Part 1 Cohort 5 10 mg/kg LYT-200 every 2 weeks·and 5 more
    All 10

    Part 1 Cohort 1 0.2 mg/kg LYT-200 every 2 weeks · Part 1 Cohort 2 0.63 mg/kg LYT-200 every 2 weeks · Part 1 Cohort 3 2 mg/kg LYT-200 every 2 weeks · Part 1 Cohort 4 6.3 mg/kg LYT-200 every 2 weeks · Part 1 Cohort 5 10 mg/kg LYT-200 every 2 weeks · Part 1 Cohort 6 16 mg/kg LYT-200 every 2 weeks · Part 1 Cohort 7 10 mg/kg LYT-200 weekly · Part 1 Cohort 11 6.3 mg/kg LYT-200 + tislelizumab weekly · Part 1 Cohort 12 16 mg/kg LYT-200 + tislelizumab weekly · Part 1 Cohort 13 6.3 mg/kg LYT-200 + tislelizumab weekly

    ; arms removed: Part 1 single agent dose escalation·Part 1 combination agents dose expansion·Part 2
    + 5 other changes: index terms, verification date, description, conditions and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04666688
Lead sponsor
PureTech
Responsible party
Sponsor
First posted
Dec 14, 2020
Start date
Dec 11, 2020
Primary completion
Dec 12, 2024
Completion
Dec 12, 2024
Results posted
Nov 16, 2026
Last update
Nov 16, 2026

Study contacts

Aleksandra Filipovic, MD, Ph.D.
study director · PureTech Health

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion